UK Life Sciences Vows To Maximize Post-Brexit Opportunities
The UK is “open for business” as far as the life-sciences sector is concerned, and those with ministerial and departmental oversight are promising to work with the realities – still largely unknown – that the country's exit from the EU will bring forth. Such was the tone of UK Office for Life Sciences’ director Nicole Mather, speaking to health-care industry delegates Sept. 15 in London.
You may also be interested in...
The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.
One aim of the soon-to-be-published proposals is to make the health environment in the UK more innovation-friendly, in particular for medtech and digital health products. The final report on the government’s Accelerated Access Review should be out by the end of the month.
How should the UK medtech regulatory landscape look once the country separates from the EU? Phil Brown of the Association of British Healthcare Industries is helping to spearhead the effort to shape industry’s policy position on the matter. He spoke to Medtech Insight about options on the table and some potential implications.